Germany’s Merck KGaA (MRCG.DE) said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics (SWTX.O) for about $3.5 billion, a deal that could give it access to a recently approved rare disease drug and expand its portfolio of experimental cancer treatments. Merck said that the companies are in discussions on the basis of a price of around $47 per share, which gives a valuation of roughly $3.5 billion, according to Reuters calculations. The SpringWorks acquisition would rank as one of the biggest pharma deals for the German healthcare and technology group in recent years, boosting its ongoing efforts to build out its cancer treatment pipeline.
Read the full article: Germany’s Merck Says in Late-Stage Discussions to Buy SpringWorks for $3.5B //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/germanys-merck-nears-roughly-35-billion-deal-springworks-wsj-reports-2025-04-24/